A Recombinant Human Parainfluenza Virus Type 3 (PIV3) in Which the Nucleocapsid N Protein Has Been Replaced by That of Bovine PIV3 Is Attenuated in Primates
Open Access
- 1 April 2000
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 74 (7) , 3188-3195
- https://doi.org/10.1128/jvi.74.7.3188-3195.2000
Abstract
The shipping fever (SF) and Kansas (Ka) strains of bovine parainfluenza virus type 3 (BPIV3) are restricted in their replication in rhesus monkeys 100- to 1,000-fold compared to human parainfluenza virus type 3 (HPIV3), and the Ka strain also was shown to be attenuated in humans. To initiate an investigation of the genetic basis of the attenuation of BPIV3 in primates, we produced viable chimeric HPIV3 recombinants containing the nucleoprotein (N) open reading frame (ORF) from either BPIV3 Ka or SF in place of the HPIV3 N ORF. These chimeric recombinants were designated cKa-N and cSF-N, respectively. Remarkably, cKa-N and cSF-N grew to titers comparable to those of their HPIV3 and BPIV3 parents in LLC-MK2 monkey kidney and Madin-Darby bovine kidney cells. Thus, the heterologous nature of the N protein did not impede replication in vitro. However, cKa-N and cSF-N were each restricted in replication in rhesus monkeys to a similar extent as Ka and SF, respectively. This identified the BPIV3 N protein as a determinant of the host range restriction of BPIV3 in primates. These chimeras thus combine the antigenic determinants of HPIV3 with the host range restriction and attenuation phenotype of BPIV3. Despite their restricted replication in rhesus monkeys, the chimeric viruses induced a level of resistance to HPIV3 challenge in these animals which was indistinguishable from that conferred by immunization with HPIV3. The infectivity, attenuation, and immunogenicity of these BPIV3/HPIV3 chimeras suggest that the modified Jennerian approach described in the present report represents a novel method to design vaccines to protect against HPIV3-induced disease in humans.Keywords
This publication has 21 references indexed in Scilit:
- The immunogenicity and efficacy of intranasally or parenterally administered replication-deficient vaccinia-parainfluenza virus type 3 recombinants in rhesus monkeysVaccine, 1998
- Efficacy of the Rhesus Rotavirus–Based Quadrivalent Vaccine in Infants and Young Children in VenezuelaNew England Journal of Medicine, 1997
- Evaluation of a live attenuated bovine parainfluenza type 3 vaccine in two- to six-month-old infantsThe Pediatric Infectious Disease Journal, 1996
- A Live Human Parainfluenza Type 3 Virus Vaccine Is Attenuated and Immunogenic in Healthy Infants and ChildrenThe Journal of Infectious Diseases, 1995
- A Live Attenuated Bovine Parainfluenza Virus Type 3 Vaccine Is Safe, Infectious, Immunogenic, and Phenotypically Stable in Infants and ChildrenThe Journal of Infectious Diseases, 1995
- The complete nucleotide sequence of two cold-adapted, temperature-sensitive attenuated mutant vaccine viruses (cp12 and cp45) derived from the JS strain of human parainfluenza virus type 3 (PIV3)Virus Research, 1993
- Cold-passaged human parainfluenza type 3 viruses contain ts and non-ts mutations leading to attenuation in rhesus monkeysVirus Research, 1992
- Attenuation of Bovine Parainfluenza Virus Type 3 in Nonhuman Primates and Its Ability to Confer Immunity to Human Parainfluenza Virus Type 3 ChallengeThe Journal of Infectious Diseases, 1988
- Dose Response of Influenza A/Washington/897/80 (H3N2) Avian-Human Reassortant Virus in Adult VolunteersThe Journal of Infectious Diseases, 1985
- Cold adaptation of parainfluenza virus type 3: Induction of three phenotypic markersJournal of Medical Virology, 1982